<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328939</url>
  </required_header>
  <id_info>
    <org_study_id>ITI105316</org_study_id>
    <nct_id>NCT00328939</nct_id>
  </id_info>
  <brief_title>ARIXTRA Local Study For Registration In China.</brief_title>
  <official_title>Randomized, Single Blind, Parallel Study to Compare the Safety and Efficacy of ARIXTRA to Enoxaparine in Patients Undergoing Elective Major Hip or Knee Replacement or a Revision of Components.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a local registration study in China to compare the safety and efficacy of ARIXTRA to
      Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of
      components.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of overall DVT (deep vein thrombosis) events confirmed by ultrasound result within day 5-11 post operation.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of DVT with symptom and non-fatal PE (pulmonary embolism). Occurrence of fatal PE.</measure>
  </secondary_outcome>
  <enrollment>240</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Knee Replacement</condition>
  <condition>Hip Replacement</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARIXTRA infusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparine infusion</intervention_name>
    <other_name>ARIXTRA infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients undergoing either an elective major hip or knee replacement or revision.

          -  Signed written informed consent. Men or women of non-child bearing potential(i.e.,
             post menopausal or with hysterectomy of bilateral tubule ligation) or women of
             childbearing potential without any plan to have a child.

        Exclusion criteria:

          -  History of serious active bleeding in last 3 month

          -  Concurrent or history of thrombocytopenia ( Platelet&lt; 100x109/L)

          -  History of hypersensitivity reaction to heparin, Low molecular weight heparin or pork
             product

          -  Acute bacterial endocarditis

          -  Congenital or acquired bleeding disease in last 3 months

          -  Concurrent uncontrolled ulcer or gastrointestinal disease with blood vessel dysplasia

          -  Concurrent hemorrhagic cerebrovascular disease or surgical history in cerebral, spine
             or eye

          -  Conditions need to leave a tubule in intradural or extradural

          -  Contraindication to anticoagulant or condition required to take long term oral
             anticoagulant

          -  Abnormality in hepatic (&gt;1.5x UNL), renal (Clcr &lt; 30ml/min) or cardiac function,
             uncontrolled hypertension or tumor Concurrent disorder of blood vessel in lower limb

          -  Positive result in Human Chorionic Gonadotropin test Participated in any other
             investigational study on Deep Vein Thrombosis prevention in last 90 days.

          -  Concurrently to have hip and knee or double hip/knee replacement at the same time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2006</study_first_submitted>
  <study_first_submitted_qc>May 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2006</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARIXTRA</keyword>
  <keyword>prevention of DVT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

